Boston Scientific Q3 FY25: where the revenue came from and where it went
The whole income statement of Boston Scientific for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Nov 3, 2025
Revenue$5.07B
+20% year over year
Gross profit$3.54B
70% margin
Operating profit$1.05B
21% margin
Net profit$0.76B
15% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 5.07 | 100% | +20% |
| Electrophysiology | 0.87 | 17% | +64% |
| Global endoscopy | 0.75 | 15% | +10% |
| Peripheral interventions | 0.70 | 14% | +17% |
| Interventional cardiology | 0.69 | 14% | +4% |
| Urology & pelvic health | 0.68 | 13% | +28% |
| Cardiac rhythm management | 0.58 | 11% | +3% |
| Watchman | 0.51 | 10% | +35% |
| Neuromodulation | 0.29 | 6% | +9% |
| Cost of revenue | −1.52 | 30% | |
| Gross profit | 3.54 | 70% margin | +1pp |
| SG&A | −1.74 | 34% | −3pp |
| Other | −0.75 | 15% | +0pp |
| Operating profit | 1.05 | 21% margin | +3pp |
| Interest & other costs | −0.11 | ||
| Tax | −0.18 | ||
| Net profit | 0.76 | 15% margin | +4pp |
182 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest